Gossamer Bio Announces Third-Quarter 2026 Results and Business Update
Gossamer Bio announced its third-quarter 2026 financial results and provided a business update.
Story updates
09:01:38 PM UTC
SquawkNews
New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 — — Struct
Gossamer Bio, Inc. (NASDAQ:GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease…